TRANSCRIPT 🔗
WEBVTT
00:00:05.919 --> 00:00:10.320
Anthropic also bought another company, Coefficient Bio.
00:00:10.560 --> 00:00:19.280
They're opening uh a wet lab uh in the Bay Area, and they've got partnerships with six of the major pharma players, including Bristol Myers Squibb.
00:00:19.359 --> 00:00:26.000
And venture capitalists are starting to invest with the idea of, hey, I can sell my company not to MerkerPfizer, but maybe to Anthropic.
00:00:26.239 --> 00:00:27.920
So that's kind of what's going on.
00:00:28.879 --> 00:00:29.760
Does it mean anything?
00:00:30.320 --> 00:00:34.560
Well, I think it means it means that the well, there's two key implications.
00:00:34.799 --> 00:00:50.079
One, that these models might be the AI platforms might be directly relevant to transforming the way we assess, invent, and then deliver medicine in a much faster, more personalized, more scalable ways.
00:00:50.240 --> 00:01:00.640
I mean, the fact that one dude could, you know, it used to be, it's like a magic trick that some guy, a m a man could it's like sort of low, though the joke's about the one-man band.
00:01:01.200 --> 00:01:26.799
But what the Frontier Labs create are the opportunities to create quasi or totally independent agents, sort of thinking units that then can work together, like let's call it an agentic layer, to actually execute tasks, pursue business, do research, and potentially drive insights and potentially drive manufacturing of new drugs.
00:01:26.959 --> 00:01:45.439
It's pretty wild to think that um the this you know the the the two billion dollars and thousands of people in multiple companies that it normally would take to create a drug might be solved with a bunch of uh digital bots, if you will, that are agentic.
00:01:46.239 --> 00:01:47.840
That don't need any of that.
00:01:48.319 --> 00:01:52.319
And and I guess, Dave, what's this what do you think?
00:01:52.640 --> 00:02:06.480
Because historically our the biopharmaceutical industry, people know about Moore's Law, which is that we as we uh that computing power and cost goes up by factors, you know, every few years.
00:02:06.640 --> 00:02:10.319
It gets twice as fast and is half and costs half as much.
00:02:10.560 --> 00:02:17.280
If you map computing power and cost, you see this curve of incredible yields and low and and lowering costs.
00:02:17.520 --> 00:02:24.159
If you look at biopharmaceuticals, it's increasing costs and increasing time.
00:02:24.400 --> 00:02:28.159
Uh it's the it's uh literally a reversed Moore's law.
00:02:28.479 --> 00:02:31.360
And this could completely reverse that, I think.
00:02:32.080 --> 00:02:34.159
Isn't that the implication of what you're suggesting?
00:02:34.240 --> 00:02:37.280
Aaron Powell I guess a reverse Moore's law would be like uh e-room.
00:02:37.360 --> 00:02:38.960
Is that is that Moore spelled backwards?
00:02:39.199 --> 00:02:41.599
So uh maybe maybe that's what it will be.
00:02:42.000 --> 00:02:43.599
John, one of the things is very hard.
00:02:43.919 --> 00:02:50.000
I'm glad you brought up Moore's law because it's very difficult for the mind to comprehend exponential changes.
00:02:50.159 --> 00:02:52.719
You know, we can go and say Are you talking about me?
00:02:53.759 --> 00:02:56.719
No, I think you could do it, but I think for I say it's difficult.
00:02:56.960 --> 00:02:57.439
But it's hard.
00:02:57.599 --> 00:02:58.159
It's hard, John.
00:02:58.400 --> 00:03:00.719
So it's hard to look and you and you say, like, what's the implication?
00:03:00.879 --> 00:03:03.360
You can look and say, wow, these bots are going to do everything.
00:03:03.599 --> 00:03:04.400
I don't know.
00:03:04.639 --> 00:03:12.960
But the but one way to look at it is let's let's understand what's happened already and what did those steps tell us, and maybe in these particular acquisitions.
00:03:13.120 --> 00:03:20.800
So and from the just from what's happening with these companies and what it means for the business strategy of Anthropic, which still has to go out and raise money from people.
00:03:21.039 --> 00:03:24.639
So they previously said they were just a software platform, not a drug developer.
00:03:24.800 --> 00:03:38.560
Now it's actually owning assets, so that has some potential conflicts with its partners like BMS, Crystal Myers Squib, and then there's concerns, you know, things they might be concerned about their IP leaking out, overlap of therapeutics.
00:03:38.719 --> 00:03:43.280
And then I'm always interested in these things, you know, like this the idea of the one-person biotech.
00:03:43.439 --> 00:03:44.080
Well, what does that mean?
00:03:44.319 --> 00:03:48.879
So, first of all, there have been there's a lot of virtual biotechs that are out there.
00:03:49.039 --> 00:03:50.000
You know, we work with some of them.
00:03:50.080 --> 00:03:52.960
After we work with one that has no employees, if you can believe that.
00:03:53.120 --> 00:03:57.599
But um, it's pretty common to go and coordinate external resources.
00:03:57.759 --> 00:04:00.879
The CROs, contract research organizations are outsourced.
00:04:01.039 --> 00:04:05.919
And so, you know, it's often a company with one or two people might be able to orchestrate them.
00:04:06.080 --> 00:04:11.919
Now, the software is accelerating that, but you know, that is just this is just preclinical.
00:04:12.000 --> 00:04:13.280
This is a mouse, it's not a person.
00:04:13.360 --> 00:04:20.000
It's in the physical biology, the wet lab throughput, you know, those are bound by just whatever execution speed you could have.
00:04:20.160 --> 00:04:29.439
It reminds me a little bit of something from 20 years ago, or so when there was high throughput screening, when you're going to be able to go through all these different molecules very quickly and try to find the right targets.
00:04:29.600 --> 00:04:37.519
So it's sped up one part of the process, but we we haven't, it hasn't made a dramatic, such a dramatic impact on the rest of them.
00:04:37.600 --> 00:04:40.879
So that's what I'm seeing at the moment is the next step.